{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:44:22Z","timestamp":1789641862579,"version":"4.0.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dextromethorphan (d-3-methoxy-17-methylmorphinan, DXM) is a commonly used antitussive with a favorable safety profile. Previous studies have demonstrated that DXM has anti-inflammatory and immunomodulatory properties; however, the effect of DXM in rheumatoid arthritis (RA) remains unknown. Herein, we found that DXM treatment attenuated arthritis severity and proinflammatory cytokine expression levels, including TNF-\u03b1, IL-6, and IL-17A, in paw tissues of CIA mice. DXM treatment also reduced serum TNF-\u03b1, IL-6, and IL-17A levels of CIA mice and patients with RA. DXM further decreased the production of anti-CII IgG, IFN-\u03b3, and IL-17A in collagen-reactive CD4<jats:sup>+<\/jats:sup>T cells extracted from the lymph nodes of CIA mice.<jats:italic>In vitro<\/jats:italic>incubation of bone marrow\u2013derived dendritic cells with DXM limited CD4<jats:sup>+<\/jats:sup>T-cell proliferation and inflammatory cytokine secretion. In conclusion, our results showed that DXM attenuated arthritis symptoms in CIA mice and significantly reduced proinflammatory cytokines in patients with RA, suggesting that it can be used as an anti-arthritic agent.<\/jats:p>","DOI":"10.1038\/s41598-017-11378-8","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T22:18:01Z","timestamp":1504736281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis"],"prefix":"10.1038","volume":"7","author":[{"given":"Der-Yuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hsuan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Ho","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,12]]},"reference":[{"key":"11378_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Eng.l J. Med. 344, 907\u2013916 (2001).","journal-title":"N. Eng.l J. Med."},{"key":"11378_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2007","unstructured":"Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature. 423, 356\u2013361 (2007).","journal-title":"Nature."},{"key":"11378_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB McInnes","year":"2007","unstructured":"McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429\u2013442 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"11378_CR4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/ard.61.10.870","volume":"61","author":"RL Van Bezooijen","year":"2002","unstructured":"Van Bezooijen, R. L., van Der Wee-Pals, L., Papapoulos, S. E. & Lowik, C. W. Interleukin 17 synergies with tumor necrosis factor alpha to induce cartilage destruction in vitro. Ann. Rheum. Dis. 61, 870\u2013876 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"11378_CR5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/ar294","volume":"3","author":"M Chabaud","year":"2001","unstructured":"Chabaud, M., Lubberts, E., Joosten, L., van den Berg, W. & Miossec, P. L-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis. Res. Ther. 3, 169\u2013177 (2001).","journal-title":"Arthritis. Res. Ther."},{"key":"11378_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/ard.2003.016014","volume":"63","author":"SB Cohen","year":"2004","unstructured":"Cohen, S. B. et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63, 1062\u20131068 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"11378_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/art.21655","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis. Rheum. 54, 1063\u20131074 (2006).","journal-title":"Arthritis. Rheum."},{"key":"11378_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/rheumatology\/keq325","volume":"50","author":"W Kievit","year":"2011","unstructured":"Kievit, W. et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Rheumatology. 50, 196\u2013203 (2011).","journal-title":"Rheumatology."},{"key":"11378_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2014","unstructured":"McInnes, I. B. et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomized, placebo-controlled study. Ann. Rheum. Dis. 74, 694\u2013702 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"11378_CR10","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/art.38617","volume":"66","author":"MC Genovese","year":"2014","unstructured":"Genovese, M. C. et al. A phase II randomized study of subcutaneous ixekizumab, an anti-IL-17 monoclonal antibody, in rheumatoid arthritis patients who were na\u00efve to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis. Rheum. 66, 1693\u20131704 (2014).","journal-title":"Arthritis. Rheum."},{"key":"11378_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492\u2013509 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"11378_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","volume":"48","author":"N Vastesaeger","year":"2009","unstructured":"Vastesaeger, N., Xu, S., Aletaha, D., St Clair, E. W. & Smolen, J. S. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 48, 1114\u20131121 (2009).","journal-title":"Rheumatology (Oxford)."},{"key":"11378_CR13","doi-asserted-by":"crossref","unstructured":"K. Visser K et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analysis from the BeSt study. Ann. Rheum. Dis. 69, 1333\u20131337 (201).","DOI":"10.1136\/ard.2009.121160"},{"key":"11378_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/030006058301100206","volume":"11","author":"H Matthys","year":"1983","unstructured":"Matthys, H., Bleicher, B. & Bleicher, U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J. Int. Med. Res. 11, 92\u2013100 (1983).","journal-title":"J. Int. Med. Res."},{"key":"11378_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1124\/jpet.102.043166","volume":"305","author":"Y Liu","year":"2003","unstructured":"Liu, Y. et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 305, 212\u2013218 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"11378_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/cvr\/cvp043","volume":"82","author":"SL Liu","year":"2009","unstructured":"Liu, S. L. et al. Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice. Cardiovasc. Res. 82, 161\u2013169 (2009).","journal-title":"Cardiovasc. Res."},{"key":"11378_CR17","first-page":"395","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang, W. et al. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB. J. 19, 395\u2013397 (2005).","journal-title":"FASEB. J."},{"key":"11378_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1128\/AAC.00950-10","volume":"55","author":"MH Li","year":"2011","unstructured":"Li, M. H. et al. Dextromethorphan efficiently increases bactericidal activity, attenuates inflammatory responses, and prevents group a streptococcal sepsis. Antimicrob. Agents. Chemother. 55, 967\u2013973 (2011).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"11378_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bcp.2004.10.003","volume":"69","author":"G Li","year":"2005","unstructured":"Li, G. et al. Protective effect of dextromethorphan against endotoxic shock in mice. Biochem. Pharmacol. 69, 233\u2013234 (2005).","journal-title":"Biochem. Pharmacol."},{"key":"11378_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/j.1538-7836.2008.03082.x","volume":"6","author":"PY Liu","year":"2008","unstructured":"Liu, P. Y. et al. Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers. J. Thromb. Haemost. 6, 1685\u20131692 (2008).","journal-title":"J. Thromb. Haemost."},{"key":"11378_CR21","doi-asserted-by":"crossref","unstructured":"Chen, D.Y. et al. Dextromethorphan inhibits activations and functions in dendritic cells. Clin. Develop. Immunol. 2013:125643 (2013).","DOI":"10.1155\/2013\/125643"},{"key":"11378_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.autrev.2007.08.001","volume":"7","author":"YG Cho","year":"2007","unstructured":"Cho, Y. G., Cho, M. L., Min, S. Y. & Kim, H. Y. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun. Rev. 7, 65\u201370 (2007).","journal-title":"Autoimmun. Rev."},{"key":"11378_CR23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269\u20131275 (2007).","journal-title":"Nat. Protoc."},{"key":"11378_CR24","doi-asserted-by":"publisher","first-page":"R784","DOI":"10.1186\/ar1733","volume":"7","author":"K K. Raza","year":"2005","unstructured":"K. Raza, K. et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cells and stromal cell origin. Arthritis. Res. Ther. 7, R784\u2013795 (2005).","journal-title":"Arthritis. Res. Ther."},{"key":"11378_CR25","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/eji.200838535","volume":"38","author":"KH Mills","year":"2008","unstructured":"Mills, K. H. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol. 38, 2636\u20132649 (2008).","journal-title":"Eur. J. Immunol."},{"key":"11378_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048635","volume":"7","author":"SM Farooq","year":"2012","unstructured":"Farooq, S. M. & Ashour, H. M. Type II collagen induces peripheral tolerance in BALB\/c mice via the generation of CD8\u2009+\u2009T regulatory cells. PLoS One. 7, e48635 (2012).","journal-title":"PLoS One."},{"key":"11378_CR27","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1111\/jcmm.12376","volume":"18","author":"SM Farooq","year":"2014","unstructured":"Farooq, S. M., Kumar, A. & Ashour, H. M. Eye-mediated immune tolerance to Type II collagen in arthritis-prone strains of mice. J. Cell. Mol. Med. 18, 2512\u20138 (2014).","journal-title":"J. Cell. Mol. Med."},{"key":"11378_CR28","volume":"2016","author":"SP Wang","year":"2016","unstructured":"Wang, S. P., Lin, S. C. & Li, S. et al. Potent Antiarthritic Properties of Phloretin in Murine Collagen-Induced Arthritis. Evid. Based. Complement. Alternat. Med. 2016, 9831263 (2016).","journal-title":"Evid. Based. Complement. Alternat. Med."},{"key":"11378_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/13543776.18.7.723","volume":"18","author":"LD Quan","year":"2009","unstructured":"Quan, L. D., Thiele, G. M. & Tian, J. et al. The Development of Novel Therapies for Rheumatoid Arthritis. Expert. Opin. Ther. Pat. 18, 723\u2013738 (2009).","journal-title":"Expert. Opin. Ther. Pat."},{"key":"11378_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0009-9236(96)90056-9","volume":"60","author":"DA Capon","year":"1996","unstructured":"Capon, D. A. et al. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin. Pharmacol. Thera. 60, 295\u2013307 (1996).","journal-title":"Clin. Pharmacol. Thera."},{"key":"11378_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan shaw","year":"2008","unstructured":"Reagan shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB. J. 22, 659\u2013661 (2008).","journal-title":"FASEB. J."},{"key":"11378_CR32","first-page":"3","volume":"65","author":"CO Bingham 3rd","year":"2002","unstructured":"Bingham, C. O. 3rd The pathogenesis of rheumatoid arthritis pivotal cytokines involved in bone degradation and inflammation. J. Rheumatol. Suppl 65, 3\u20139 (2002).","journal-title":"J. Rheumatol. Suppl"},{"key":"11378_CR33","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00198-013-2279-8","volume":"24","author":"K Wu","year":"2013","unstructured":"Wu, K. et al. Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-\u03baB activation. Osteoporos. Int. 24, 2201\u20132214 (2013).","journal-title":"Osteoporos. Int."},{"key":"11378_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/jir.2014.0149","volume":"35","author":"P Bhattacharya","year":"2015","unstructured":"Bhattacharya, P., Budnick, I. & Singh, M. et al. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J. Interferon Cytokine Res. 35, 585\u201399 (2015).","journal-title":"J. Interferon Cytokine Res."},{"key":"11378_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cyto.2015.05.030","volume":"75","author":"P Bhattacharya","year":"2015","unstructured":"Bhattacharya, P., Thiruppathi, M. & Elshabrawy, H. A. et al. GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine. 75, 261\u201371 (2015).","journal-title":"Cytokine."},{"key":"11378_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/mus.23488","volume":"46","author":"J Rowin","year":"2012","unstructured":"Rowin, J., Thiruppathi, M. & Arhebamen., E. et al. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 46, 449\u201353 (2012).","journal-title":"Muscle Nerve."},{"key":"11378_CR37","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.4049\/jimmunol.177.4.2681","volume":"177","author":"SA Yoo","year":"2006","unstructured":"Yoo, S. A. et al. Calcineurin is expressed and plays a critical role in inflammatory arthritis. J. Immunol. 177, 2681\u20132690 (2006).","journal-title":"J. Immunol."},{"key":"11378_CR38","doi-asserted-by":"publisher","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","volume":"89","author":"RO Williams","year":"1992","unstructured":"Williams, R. O., Feldmann, M. & Maini RN, R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784\u20139788 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11378_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2106\/00004623-197153010-00007","volume":"53","author":"L Rosenberg","year":"1971","unstructured":"Rosenberg, L. Chemical basis for the histological use of safranin O in the study of articular cartilage. J. Bone. Joint. Surg. Am. 53, 69\u201382 (1971).","journal-title":"J. Bone. Joint. Surg. Am."},{"key":"11378_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/ard.59.7.529","volume":"59","author":"J Dudler","year":"2000","unstructured":"Dudler, J., Renggli Zulliger, N., Busso, N., Lotz, M. & So, A. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann. Rheum. Dis. 59, 529\u2013532 (2000).","journal-title":"Ann. Rheum. Dis."},{"key":"11378_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo, M. L. et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis. Rheum. 38, 44\u201348 (1995).","journal-title":"Arthritis. Rheum."},{"key":"11378_CR42","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. The 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis. Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis. Rheum."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11378-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:16:57Z","timestamp":1719429417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11378-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,12]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11378"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-11378-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,12]]},"assertion":[{"value":"22 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11353"}}